Please assess the completion status of the following clinical trial:

Trial Title: Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of AATD~* Women of childbearing potential must have a negative pregnancy test, cannot be breast feeding, and must be willing to use contraception~* Willing to provide written informed consent and to comply with study requirements~* Non-smoker for at least 1 year~* No abnormal finding of clinical relevance at screening~Exclusion Criteria:~* Clinically significant health concerns other than AATD~* Previous diagnosis or diagnosis at Screening of definitive liver cirrhosis~* Regular use of alcohol within one month prior to Screening~* Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study involving therapeutic intervention~* Use of illicit drugs within 1 year prior to Screening~Note: additional inclusion/exclusion criteria may apply, per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Fazirsiran (TAK-999, ARO-AAT) Cohort 1 (Type: EXPERIMENTAL): Administered on Day 1, Weeks 4 and 16 for a minimum of 3 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 12 additional doses.
- Fazirsiran (TAK-999, ARO-AAT) Cohort 1b (Type: EXPERIMENTAL): Administered on Day 1, Weeks 4 and 16, for a minimum of 3 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 12 additional doses.
- Fazirsiran (TAK-999, ARO-AAT) Cohort 2 (Type: EXPERIMENTAL): Administered on Day 1, Weeks 4, 16, 28 and 40 for a minimum of 5 doses.~Treatment Extension (optional enrollment): Administered every 12 weeks for 12 additional doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).